Breaking News
Get 40% Off 0
🚨 Volatile Markets? Find Hidden Gems for Serious Outperformance
Find Stocks Now
Close

Adaptimmune Therapeutics Plc (ADAP)

Create Alert
New!
Create Alert
Website
  • As an alert notification
  • To use this feature, make sure you are signed-in to your account
Mobile App
  • To use this feature, make sure you are signed-in to your account
  • Make sure you are signed-in with the same user profile

Condition

Frequency

Once
%

Frequency

Frequency

Follow Adaptimmune Therapeutics's earnings

Delivery Method

Status

Add to/Remove from a Portfolio Add to Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
1.190 0.000    0.00%
03/05 - Closed. Currency in USD ( Disclaimer )
After Hours
1.200
+0.010
+0.840%
21:52:25 - Real-time Data
  • Volume: 850,041
  • Bid/Ask: 1.210 / 1.230
  • Day's Range: 1.170 - 1.240
Type:  Equity
Market:  United States
Adaptimmune Therapeutics 1.190 0.000 0.00%

Adaptimmune Therapeutics Plc Latest Cash Flow Statement

 
Use the Adaptimmune Therapeutics Plc cash flow statement to assess the changes in ADAP's cash and cash equivalents.

The ADAP cash flow chart shows Net Income, Cash from Operating, Financing and Investing Activities, as well as Adaptimmune Therapeutics free cash flow, yield and ending cash balance.
AnnualQuarterly
Advanced Cash Flow Statement
Period Ending: 2023
31/12
2023
30/09
2023
30/06
2023
31/03
Period Length: 0 Months 0 Months 0 Months 0 Months
Net Income/Starting Line -47.92 -45.6 -21.39 1.04
Cash From Operating Activities -14.68 -45.16 -43.76 -37.28
Depreciation/Depletion 2.81 2.82 2.16 1.66
Amortization 0.065 0.069 0.067 0.186
Deferred Taxes - - - -
Non-Cash Items 2.09 2.24 -18.72 2.48
Cash Receipts - - - -
Cash Payments - - - -
Cash Taxes Paid 4 - - -
Cash Interest Paid - - - -
Changes in Working Capital 28.28 -4.7 -5.88 -42.65
Cash From Investing Activities 68.2 57.31 2.69 48.34
Capital Expenditures -0.827 -0.289 -1.22 -2.35
Other Investing Cash Flow Items, Total 69.02 57.6 3.91 50.69
Cash From Financing Activities 0.074 0.596 0.014 0.196
Financing Cash Flow Items - - - -
Total Cash Dividends Paid - - - -
Issuance (Retirement) of Stock, Net 0.074 0.596 0.014 0.196
Issuance (Retirement) of Debt, Net - - - -
Foreign Exchange Effects -0.313 -0.324 0.501 -0.671
Net Change in Cash 53.94 12.87 -41.24 11.84
Beginning Cash Balance 90.05 77.19 118.21 108.02
Ending Cash Balance 143.99 90.06 76.97 119.87
Free Cash Flow -31.67 -25.24 -21.53 4.69
Free Cash Flow Growth -25.47 -17.27 -559.44 365.52
Free Cash Flow Yield -8.61 -25.75 -26.34 -22.1
* In Millions of USD (except for per share items)
InvestingPro
Go to Dashboard InvestingPro

Unlock access to over 1000 metrics with InvestingPro

View advanced insights on the cash flow statement, including growth rates and metrics that provide an in-depth view of the company's historical and forecasted financial performance.

 
Comment Guidelines

We encourage you to use comments to engage with users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind: 

  • Enrich the conversation
  • Stay focused and on track. Only post material that’s relevant to the topic being discussed.
  • Be respectful. Even negative opinions can be framed positively and diplomatically.
  •  Use standard writing style. Include punctuation and upper and lower cases.
  • NOTE: Spam and/or promotional messages and links within a comment will be removed
  • Avoid profanity, slander or personal attacks directed at an author or another user.
  • Don’t Monopolize the Conversation. We appreciate passion and conviction, but we also believe strongly in giving everyone a chance to air their thoughts. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

ADAP Price Commentary

Write your thoughts about Adaptimmune Therapeutics Plc
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
Akis Tryfonos
Akis Tryfonos Jan 12, 2022 4:01
Saved. See Saved Items.
This comment has already been saved in your Saved Items
One year after is under 4 dollars ….
Billy Rix
Billy Rix Jan 22, 2021 23:02
Saved. See Saved Items.
This comment has already been saved in your Saved Items
"Aim to commercialize ADP-A2M4 as the first engineered TCR T-cell product in the US in 2022" one to load up on this year whilst still under $6? pipeline looks great, lots of chances for some run ups in share price?
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Continue with Google
or
Sign up with Email